scholarly journals Examining the relationship between traditional Chinese medicine and conventional medicine in breast cancer patients medicated with estrogen antagonists

2012 ◽  
Vol 2 (1) ◽  
pp. 11 ◽  
Author(s):  
Jill Hervik ◽  
Odd Mjaland
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Conventional Medicine ◽  
Breast Cancer Patients ◽  
Complementary Role ◽  
Estrogen Receptor Positive ◽  
The Relationship ◽  
Traditional Chinese Medical ◽  
Estrogen Antagonists

Breast cancer is the most common type of cancer among women, with a 10.4% incidence rate worldwide. It is the fifth most common cause of death. Treatment includes surgery, radiation and drugs. Conventional treatment of estrogen receptor positive types of tumors involves the use of hormone therapy. The side-effects of these drugs, <em>i.e.</em> menopausal type symptoms, are an extra burden to women with breast cancer. Further use of drugs to treat such side-effects often provokes adverse symptoms, prompting a search for alternative types of treatment. This paper aims to review research into the use of traditional Chinese medical acupuncture to combat side-effects in breast cancer patients medicated with estrogen antagonists, and examine its complementary role.

scholarly journals Is monitoring mean platelet volume necessary in breast cancer patients?

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 450-455
Author(s):  
Halil Taskaynatan ◽  
Ahmet Alacacioglu ◽  
Yuksel Kucukzeybek ◽  
Umut Varol ◽  
Yasar Yildiz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Mean Platelet Volume ◽  
Breast Cancer Patients ◽  
Platelet Volume ◽  
Adjuvant Hormone Therapy ◽  
Relationship Of ◽  
The Relationship

AbstractBackgroundMean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy.MethodsData of 261 patients who had pathologically confirmed estrogen or progesterone receptor positive invasive breast cancer and had received hormonotherapy for at least a 5-year period were retrospectively analyzed. MPV levels were measured at baseline and at the first and fifth year of hormone therapy.ResultsAll patients were females and their median age was 50 years (range, 27–78 years). The mean MPV value was significantly increased in all patients in the Tmx, AI, and switch groups over time (p<0.001).ConclusionThis is the first study evaluating the relationship between the 5-year adjuvant endocrine therapy and changes in MPV values in breast cancer patients. Monitoring changes in MPV values may be predictive for severe side effects in breast cancer patients receiving hormone therapy.

scholarly journals The Relationship Between Level Anxiety And Sleeping Quality Of Breast Cancer Patients In One Day Care Chemotherapy Room

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Lucilla Suparmi ◽  
Fransisca Anjar Rina Setyani
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Day Care ◽  
P Value ◽  
Breast Cancer Patients ◽  
The Relationship ◽  
Purposive Sample ◽  
Severe Anxiety

Objective: Chemotheraphy is one of theraphy managements for breast cancer patients. Chemotherapy has some side effects like nausea, gag, alpoesia, etc. Those can increase patients’ anxiety. Then, this anxiety will give impact on sleeping quality disoeder. This research aims to identify the anxiety level of breast cancer patients in chemotheraphy ODC room.Methods: This research used crossectional design. There are 32 respondents as research sample choosen by purposive sample technic.Results: The result shows that most repondents (68,75 %) didnot feel anxiety, 15,63% got mild anxiety, 9,38% got moderate and severe anxiety, and no one got panic anxiety. Most respondents (71,87) had good sleeping quality and 28,13% had poor sleeping quality. There is no relationship between level anxiety and sleeping quality of cancer patients with P value = 0,182.Conclusion: There is no relationship between level anxiety and sleeping quality of cancer patients. Nurse should do persoal approach to patients who are still having severe anxiety and poor sleeping qualitiy.

scholarly journals A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yixuan Song ◽  
Hong Liu
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Young Patients ◽  
Breast Cancer Treatment ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Young Breast Cancer ◽  
The Relationship

AbstractDespite the fact that the long-term survival rate of breast cancer patients had been significantly improved owing to the systemic breast cancer therapies, there are still some side effects such as amenorrhea and fertility retention to be resolved, leaving it an important thing to understand the possible side effects on fertility and fertility preservation strategies while undergoing breast cancer treatment, due to the fact that most young patients hope to become pregnant and have children after breast cancer treatment. With anti-müllerian hormone (AMH) being the most sensitive marker for predicting ovarian function in young premenopausal women with breast cancer, this review is aimed to provide the additional guidance for clinical application of AMH by exploring the impacts of AMH on the fertility of young breast cancer patients, the relationship between AMH and metabolism, and the relationship between BRAC gene mutation and fertility protection strategies.

scholarly journals Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Safa Najafi ◽  
Maryam Ansari ◽  
Vahid Kaveh ◽  
Shahpar Haghighat
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Single Dose ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Injection Site Reaction ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

scholarly journals The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients

2021 ◽  
Author(s):  
Marilot C. T. Batenburg ◽  
Wies Maarse ◽  
Femke van der Leij ◽  
Inge O. Baas ◽  
Onno Boonstra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Cancer Patients ◽  
Oxygen Therapy ◽  
Radiation Toxicity ◽  
Breast Pain ◽  
Breast Cancer Patients

Abstract Purpose To evaluate symptoms of late radiation toxicity, side effects, and quality of life in breast cancer patients treated with hyperbaric oxygen therapy (HBOT). Methods For this cohort study breast cancer patients treated with HBOT in 5 Dutch facilities were eligible for inclusion. Breast cancer patients with late radiation toxicity treated with ≥ 20 HBOT sessions from 2015 to 2019 were included. Breast and arm symptoms, pain, and quality of life were assessed by means of the EORTC QLQ-C30 and -BR23 before, immediately after, and 3 months after HBOT on a scale of 0–100. Determinants associated with persistent breast pain after HBOT were assessed. Results 1005/1280 patients were included for analysis. Pain scores decreased significantly from 43.4 before HBOT to 29.7 after 3 months (p < 0.001). Breast symptoms decreased significantly from 44.6 at baseline to 28.9 at 3 months follow-up (p < 0.001) and arm symptoms decreased significantly from 38.2 at baseline to 27.4 at 3 months follow-up (p < 0.001). All quality of life domains improved at the end of HBOT and after 3 months follow-up in comparison to baseline scores. Most prevalent side effects of HBOT were myopia (any grade, n = 576, 57.3%) and mild barotrauma (n = 179, 17.8%). Moderate/severe side effects were reported in 3.2% (n = 32) of the patients. Active smoking during HBOT and shorter time (i.e., median 17.5 vs. 22.0 months) since radiotherapy were associated with persistent breast pain after HBOT. Conclusion Breast cancer patients with late radiation toxicity reported reduced pain, breast and arm symptoms, and improved quality of life following treatment with HBOT.

The relationship of self-acceptance with decision making duration in cancer patient to perform mastectomy

2021 ◽  
pp. 1-5
Author(s):  
Ayu Ratuati Setiawan ◽  
Feny Tunjungsari ◽  
Mochamad Aleq Sander
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Abnormal Growth ◽  
Self Acceptance ◽  
Observation Method ◽  
Relationship Of ◽  
The Relationship

BACKGROUND: Cancer is a disease caused by abnormal growth of body cells that turn malignant and continue to grow uncontrollably. One of the treatments for breast cancer is mastectomy. The quickness of decision-making determines the survival rate of prognosis patients. OBJECTIVE: This study aimed to determine the relationship of self-acceptance with decision-making duration in cancer patients to perform a mastectomy. METHODS: An analytic observation method with cross-sectional design. The samples were taken by purposive sampling method with 50 samples of breast cancer patients. Data collected include age, last level of education, marital status, profession, stage of cancer during mastectomy, self-acceptance score, and decision-making duration to perform a mastectomy. RESULTS: The data analyzed with the Kruskal–Wallis test. The test showed the relationship of self-acceptance (p = 0.027) with decision-making duration in breast cancer patients to perform a mastectomy. CONCLUSION: In Conclusion, there is a relationship of self-acceptance with decision-making duration in breast cancer patients to perform a mastectomy.

Sign in / Sign up

Export Citation Format

Share Document